Effect on Glycemic Control of Liraglutide in Combination With Rosiglitazone Plus Metformin Versus Rosiglitazone Plus Metformin in Subjects With Type 2 Diabetes.

Trial Profile

Effect on Glycemic Control of Liraglutide in Combination With Rosiglitazone Plus Metformin Versus Rosiglitazone Plus Metformin in Subjects With Type 2 Diabetes.

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs Liraglutide (Primary) ; Metformin; Rosiglitazone
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms LEAD-4
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Jul 2016 Results of a meta-analysis in African-American/black people with T2DM from seven phase III trials (NCT00395746, NCT00614120, NCT00294723, NCT00333151, NCT00331851, NCT00518882 and NCT00700817), published in the Diabetic Medicine
    • 25 Jun 2010 Outcomes from a pooled anlaysis of the 6 LEAD trials were reported at the 70th Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top